Cell and Tissue Preservation Market (By Type: Cell, Tissue; By Application: Therapeutics, Drug Discovery, Gene therapy, IVF treatment, Cell therapy, Research & Development; By Product: Equipment, Software, Bio-preservation Media; By End User: Biobanks, Hospitals; By Cell Provider: CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2033
The global cell and tissue preservation market size was valued at USD 4.22 billion in 2023 and it is expected to hit over USD 11.98 billion by 2033 with a remarkable CAGR of 11.01% from 2024 to 2033.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. cell and tissue preservation market size was estimated at USD 1.19 billion in 2023 and is predicted to be worth around USD 3.55 billion by 2033, at a CAGR of 11.59% from 2024 to 2033.
North America was the leading cell and tissue preservation market in 2023. The demand for the advanced healthcare technology is higher in North America. The presence of advanced healthcare infrastructure and higher government investments in the research and development in the healthcare technology has significantly driven the growth of the cell and tissue preservation market. The increased prevalence of chronic diseases among the population of US has attracted heavy investments in drug discovery and development of innovative therapeutics, which has driven the growth of the North America cell and tissue preservation market.
Asia Pacific is expected to be the most opportunistic market during the forecast period. The increasing investments in development of advanced healthcare and medical infrastructure and the presence of several top pharmaceutical companies and research organizations are significantly contributing towards the growth of the Asia Pacific cell and tissue preservation market.
The Europe cell and tissue preservation market size was calculated at USD 1.11 billion in 2023 and is projected to expand around USD 3.33 billion by 2033, poised to grow at a CAGR of 11.62% from 2024 to 2033.
| Year | Market Size (USD Billion) |
| 2023 | 1.11 |
| 2024 | 1.24 |
| 2025 | 1.38 |
| 2026 | 1.54 |
| 2027 | 1.72 |
| 2028 | 1.92 |
| 2029 | 2.15 |
| 2030 | 2.40 |
| 2031 | 2.41 |
| 2032 | 2.98 |
| 2033 | 3.33 |
The global cell and tissue preservation market is significantly driven by the rising preservation of stem cells. The rising investments towards the development of healthcare infrastructure, adoption of smart technologies, and medical innovations are expected to foster the market growth during the forecast period. The globe is witnessing an increasing prevalence of various chronic diseases such as cardiovascular diseases, range of malignancies, diabetes, neurological disorders, and many other diseases, which is significantly boosting the growth of the global cell and tissue preservation market. The improved access to the better healthcare facilities owing to the rising disposable income, presence of developed healthcare infrastructure, and rising healthcare expenditure has led to the development of innovative bio-preservation technologies and facilities.
The adoption of the cryopreservation helps to extend the shelf life of some of the cells. The recent outbreak of the COVID-19 pandemic in 2020 has forced the companies to focus on reducing the risks of cross contamination especially at the fertility clinics and centers. The increasing demand for the regenerative therapies across the globe is expected to fuel the growth of the cell and tissue preservation market. The regenerative therapies helps in the restoration of the cells and tissues caused due to the age related diseases, congenital abnormalities, and injuries. Furthermore, the growing demand for storing organs for transplantation is another major factor that is anticipated to have a significant impact on the market growth in the foreseeable future.
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 11.01% |
| Market Size in 2023 | USD 4.22 Billion |
| Market Size by 2033 | USD 11.98 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type, By Application, By Product, By End User, and By Cell Provider |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Based on the type, the cell segment led the global cell and tissue preservation market in 2023 with revenue share of 53% with a CAGR of 11.7% from 2024 to 2033. The rising demand for the cell therapies and regenerative therapies among the patients is expected to drive the market growth. Furthermore, the increasing prevalence of various diseases and the rising investments in the technological advancements to enhance the storage systems of cells is propelling the growth of this segment.
Tissue Segment is expected to be the fastest-growing segment during the forecast period. This growth is attributed to the increasing penetration of the biobanks across the globe. Furthermore, the rising demand for the regenerative medicines is significantly fostering the growth of this segment. The rising incidences of age related diseases and severe injuries are propelling the demand for the tissue preservation across the globe. The rising geriatric population across the globe is expected to further spur the growth of this segment in the forthcoming years. According to the United Nations, the elderly population across the globe is expected to reach around 2 billion by the year 2050, which will positively contribute towards the growth of the tissues segment in the cell and tissue preservation market.
On the basis of application, the therapeutics was the dominating segment that constituted revenue of around 40% in 2023 with a CAGR of 11.8% during the forecast period. The increased demand for the cell and tissue preservation for the development of therapeutics to cure various chronic and non-communicable diseases has led to the dominance of this segment across the globe. The rapidly surging prevalence of lifestyle and age related diseases is expected to foster the growth of this segment and is expected to sustain its position in the global cell and tissue preservation market throughout the forecast period.
IVF treatment segment is anticipated to exhibit highest CAGR during the forecast period. This is attributed to the rising demand for the IVF treatments across the globe. Late marriages, rising participation of women in workforce, higher preference to career over marriage, and several other factors are resulting in the declining fertility rates and growing complexities in the pregnancies. These factors are propelling the demand for the IVF treatment, which in turn is expected to drive the growth of the IVF treatment segment in the cell and tissue preservation market.
Depending on the product, the global cell and tissue preservation market was dominated by the equipment segment in 2023. The surging demand for the biobanks across the globe owing to its higher utilization in tissue, stem cell, Plasma, and DNA research has fueled the growth of the equipment segment. The equipment segment was valued at US$ 2,026 million in 2023 and it is expected to hit US$ 6,805 million in 2033, growing at a CAGR of 11.7% from 2024 to 2033. The increased adoption of the freezing and storage systems for the preservation of cells and tissues has led to the dominance of this segment in the global market. Furthermore, the high costs associated with the acquisition of the advanced and innovative equipment helped in the higher revenue generation.
Software segment is anticipated to be the most opportunistic segment during the forecast period. This rising investments in the adoption of software technologies owing to the rising trend of digitization and automation. The increasing needs for controlling costs and effectively manage the operations and inventories have fueled the adoption of the software technologies in the biobanks.
Based on the end user, the biobanks segment led the global cell and tissue preservation market accounting for over 68% of the market share in 2023. The rising demand for the stem cell preservation among the researchers has significantly fueled the growth the biobanks segment. Moreover, the rising advancements in the technology and growing investments in the research activities for the purpose of drug discovery and development of various therapeutics is further expected to drive the market growth.
The biobanks is also anticipated to be the fastest-growing segment during the forecast period. The surging number of egg and sperm banks and the rising adoption of the assisted reproductive technology is fueling the growth of the biobanks segment.
The cell and tissue preservation market is highly fragmented owing to the presence of numerous key market players. These key players are constantly engaged into various developmental strategies such as mergers, acquisitions, partnerships, collaborations, and new product launches to strengthen their position and expand their market share.
Segments Covered in the Report
By Type
By Application
By Product
By End User
By Cell Provider
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cell and Tissue Preservation Market
5.1. COVID-19 Landscape: Cell and Tissue Preservation Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cell and Tissue Preservation Market, By Type
8.1. Cell and Tissue Preservation Market, by Type, 2024-2033
8.1.1. Cell
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Tissue
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Cell and Tissue Preservation Market, By Application Type
9.1. Cell and Tissue Preservation Market, by Application Type, 2024-2033
9.1.1. Therapeutics
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Drug Discovery
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Gene therapy
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. IVF treatment
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Research & Development
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Cell therapy
9.1.6.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Cell and Tissue Preservation Market, By Product Type
10.1. Cell and Tissue Preservation Market, by Product Type, 2024-2033
10.1.1. Equipment
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Software
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Bio-preservation Media
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Cell and Tissue Preservation Market, By End User Type
11.1. Cell and Tissue Preservation Market, by End User Type, 2024-2033
11.1.1. Biobanks
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Hospitals
11.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Cell and Tissue Preservation Market, By Cell Provider Type
12.1. Cell and Tissue Preservation Market, by Cell Provider, 2024-2033
12.1.1. CD34+
12.1.1.1. Market Revenue and Forecast (2021-2033)
12.1.2. CD19+
12.1.2.1. Market Revenue and Forecast (2021-2033)
12.1.3. MSC
12.1.3.1. Market Revenue and Forecast (2021-2033)
12.1.4. iPSC
12.1.4.1. Market Revenue and Forecast (2021-2033)
12.1.5. hESC
12.1.5.1. Market Revenue and Forecast (2021-2033)
12.1.6. Tumor Cells
12.1.6.1. Market Revenue and Forecast (2021-2033)
12.1.7. Others
12.1.7.1. Market Revenue and Forecast (2021-2033)
Chapter 13. Global Cell and Tissue Preservation Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Type (2021-2033)
13.1.2. Market Revenue and Forecast, by Application (2021-2033)
13.1.3. Market Revenue and Forecast, by Product (2021-2033)
13.1.4. Market Revenue and Forecast, by End User (2021-2033)
13.1.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.1.6.2. Market Revenue and Forecast, by Application (2021-2033)
13.1.6.3. Market Revenue and Forecast, by Product (2021-2033)
13.1.6.4. Market Revenue and Forecast, by End User (2021-2033)
13.1.7. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Type (2021-2033)
13.1.8.2. Market Revenue and Forecast, by Application (2021-2033)
13.1.8.3. Market Revenue and Forecast, by Product (2021-2033)
13.1.8.4. Market Revenue and Forecast, by End User (2021-2033)
13.1.8.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.2. Market Revenue and Forecast, by Application (2021-2033)
13.2.3. Market Revenue and Forecast, by Product (2021-2033)
13.2.4. Market Revenue and Forecast, by End User (2021-2033)
13.2.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.6.2. Market Revenue and Forecast, by Application (2021-2033)
13.2.6.3. Market Revenue and Forecast, by Product (2021-2033)
13.2.7. Market Revenue and Forecast, by End User (2021-2033)
13.2.8. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.9.2. Market Revenue and Forecast, by Application (2021-2033)
13.2.9.3. Market Revenue and Forecast, by Product (2021-2033)
13.2.10. Market Revenue and Forecast, by End User (2021-2033)
13.2.11. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.12.2. Market Revenue and Forecast, by Application (2021-2033)
13.2.12.3. Market Revenue and Forecast, by Product (2021-2033)
13.2.12.4. Market Revenue and Forecast, by End User (2021-2033)
13.2.13. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.14.2. Market Revenue and Forecast, by Application (2021-2033)
13.2.14.3. Market Revenue and Forecast, by Product (2021-2033)
13.2.14.4. Market Revenue and Forecast, by End User (2021-2033)
13.2.15. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.2. Market Revenue and Forecast, by Application (2021-2033)
13.3.3. Market Revenue and Forecast, by Product (2021-2033)
13.3.4. Market Revenue and Forecast, by End User (2021-2033)
13.3.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.6.2. Market Revenue and Forecast, by Application (2021-2033)
13.3.6.3. Market Revenue and Forecast, by Product (2021-2033)
13.3.6.4. Market Revenue and Forecast, by End User (2021-2033)
13.3.7. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.8.2. Market Revenue and Forecast, by Application (2021-2033)
13.3.8.3. Market Revenue and Forecast, by Product (2021-2033)
13.3.8.4. Market Revenue and Forecast, by End User (2021-2033)
13.3.9. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.10.2. Market Revenue and Forecast, by Application (2021-2033)
13.3.10.3. Market Revenue and Forecast, by Product (2021-2033)
13.3.10.4. Market Revenue and Forecast, by End User (2021-2033)
13.3.10.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.11.2. Market Revenue and Forecast, by Application (2021-2033)
13.3.11.3. Market Revenue and Forecast, by Product (2021-2033)
13.3.11.4. Market Revenue and Forecast, by End User (2021-2033)
13.3.11.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.2. Market Revenue and Forecast, by Application (2021-2033)
13.4.3. Market Revenue and Forecast, by Product (2021-2033)
13.4.4. Market Revenue and Forecast, by End User (2021-2033)
13.4.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.6.2. Market Revenue and Forecast, by Application (2021-2033)
13.4.6.3. Market Revenue and Forecast, by Product (2021-2033)
13.4.6.4. Market Revenue and Forecast, by End User (2021-2033)
13.4.7. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.8.2. Market Revenue and Forecast, by Application (2021-2033)
13.4.8.3. Market Revenue and Forecast, by Product (2021-2033)
13.4.8.4. Market Revenue and Forecast, by End User (2021-2033)
13.4.9. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.10.2. Market Revenue and Forecast, by Application (2021-2033)
13.4.10.3. Market Revenue and Forecast, by Product (2021-2033)
13.4.10.4. Market Revenue and Forecast, by End User (2021-2033)
13.4.10.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.11.2. Market Revenue and Forecast, by Application (2021-2033)
13.4.11.3. Market Revenue and Forecast, by Product (2021-2033)
13.4.11.4. Market Revenue and Forecast, by End User (2021-2033)
13.4.11.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Type (2021-2033)
13.5.2. Market Revenue and Forecast, by Application (2021-2033)
13.5.3. Market Revenue and Forecast, by Product (2021-2033)
13.5.4. Market Revenue and Forecast, by End User (2021-2033)
13.5.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.5.6.2. Market Revenue and Forecast, by Application (2021-2033)
13.5.6.3. Market Revenue and Forecast, by Product (2021-2033)
13.5.6.4. Market Revenue and Forecast, by End User (2021-2033)
13.5.7. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Type (2021-2033)
13.5.8.2. Market Revenue and Forecast, by Application (2021-2033)
13.5.8.3. Market Revenue and Forecast, by Product (2021-2033)
13.5.8.4. Market Revenue and Forecast, by End User (2021-2033)
13.5.8.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
Chapter 14. Company Profiles
14.1. Thermo Fisher Scientific, Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Lonza
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. BD
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. MerckKGaA
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Cytiva
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Agilent Technologies, Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Avantor, Inc.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. FUJIFILM Irvine Scientific
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. BioLifeSolutions Inc.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. AMSBIO
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
14.11. Princeton CryoTech
14.11.1. Company Overview
14.11.2. Product Offerings
14.11.3. Financial Performance
14.11.4. Recent Initiatives
14.12. STEMCELL Technologies Inc.
14.12.1. Company Overview
14.12.2. Product Offerings
14.12.3. Financial Performance
14.12.4. Recent Initiatives
14.13. LGC SeraCare
14.13.1. Company Overview
14.13.2. Product Offerings
14.13.3. Financial Performance
14.13.4. Recent Initiatives
14.14. Corning Incorporated
14.14.1. Company Overview
14.14.2. Product Offerings
14.14.3. Financial Performance
14.14.4. Recent Initiatives
14.15. CellGenix GmbH
14.15.1. Company Overview
14.15.2. Product Offerings
14.15.3. Financial Performance
14.15.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
